Authors: Mazariegos G.V.; Salzedas A.A.; Zavatsky J.; Sindhi R.; Parizhskaya M.; McGhee W.; Jain A.; Reyes J.

Source: BioDrugs, Volume 14, Number 1, 1 July 2000 , pp. 31-48(18)

Publisher: Adis International

Abstract:

The current management of hepatic allograft rejection after liver transplantation in children requires effective baseline immunosuppression to prevent rejection and rapid diagnosis and treatment to manage acute rejection episodes. The subsequent impact on chronic rejection is dependent on the combination of adequate prevention and the treatment of acute rejection.

Tacrolimus is a macrolide lactone that inhibits the signal transduction of interleukin-2 (IL-2) via calcineurin inhibition. Introduced in 1989, tacrolimus was first used in the salvage of refractory acute or chronic rejection under cyclosporin or to rescue patients with significant cyclosporin-related complications. The majority of paediatric transplant centres use a combination of steroids with tacrolimus as a basic immunosuppressant regimen following paediatric liver transplantation. This combination has allowed the acute cellular rejection-free rate to increase to between 30 and 60%, while lowering the rate of refractory rejection to less than 5%. Corticosteroid-resistant rejection is commonly treated with monoclonal (muromonab CD3) or polyclonal preparations. Although most episodes of acute cellular rejection occur during the first 6 weeks after liver transplant, the appearance of late acute liver allograft rejection must raise the question of noncompliance, especially in the adolescent population. Chronic rejection is becoming increasingly rare under tacrolimus-based immunosuppression. Tacrolimus is effective in reversing refractory acute cellular rejection or early chronic rejection in patients initially treated with cyclosporin-based regimens. Patients with a history of noncompliance as well as children with autoimmune liver disease are at risk of chronic rejection. Retransplantation therapy for chronic rejection has, fortunately, become more rare in the tacrolimus era with only 3% of retransplants being performed for this indication.

Newer immunosuppressive agents are further modifying the long term management of liver allograft rejection. These include mycophenolate mofetil, rapamycin and IL-2 antibodies such as daclizumab. The development of these agents is allowing patient-specific immunosuppressive management to minimise rejection as well as the complications related to immunosuppression.

Keywords: Anti interleukin 2 monoclonal antibody, therapeuti; Children; Cyclosporin, therapeutic use; Drug withdrawal; Immunosuppressants, therapeutic use; Liver transplant rejection, prevention; Liver transplant rejection, treatment; Mycophenolate mofetil, therapeutic use; Research and development; Sirolimus, therapeutic use; Tacrolimus, therapeutic use

Document Type: Disease Management

Affiliations: 1: University of Pittsburgh Medical Center, Department of Surgery, Thomas E. Starzl Transplantation Institute, and Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA

Publication date: 2000-07-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Mazariegos G.V. ;  Salzedas A.A. ;  Zavatsky J. ;  Sindhi R. ;  Parizhskaya M. ;  McGhee W. ;  Jain A. ;  Reyes J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers